There are 3484 resources available
1913O - A randomised, multicenter phase-III study comparing doxorubicin (dox) alone versus dox with trabectedin (trab) followed by trab in non-progressive patients (pts) as first-line therapy, in pts with metastatic or unresectable leiomyosarcoma (LMS): Final results of the LMS-04 study
Presenter: Patricia Pautier
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
652O - Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Presenter: Kathryn Arbour
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
132MO - Molecular profiling of 991 prospectively recruited rare cancers patients in EUROPE: First results of ARCAGEN – an EORTC-SPECTA and EURACAN study
Presenter: Marie Morfouace
Session: Mini oral session - Basic science & translational research
Resources:
Abstract
Slides
Webcast
379MO - Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study
Presenter: Peter Schmid
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1766MO - Health-related quality of life (HRQoL) in nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients (pts) with high-risk biochemical recurrence (BCR) from the EMBARK study
Presenter: Stephen Freedland
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Introduction and scientific background
Presenter: Julien Taieb
Session: Circulating tumour DNA: A perfect fit?
Resources:
Slides
Webcast
Introduction and scientific background
Presenter: Sjoukje Oosting
Session: Immunotherapy for head and neck cancer: What, when and how long?
Resources:
Slides
Webcast
Processed meat, sugar, exercise: Prevention opportunities for oncologists
Presenter: Elisabete Weiderpass
Session: Current issues in primary prevention and screening to block the onset or development of cancer
Resources:
Slides
Webcast
Introduction to the ESMO Fellowship Programme
Presenter: Teresa Amaral
Session: YO Fellowship Session: Fellowships in Europe: Educational opportunities for young oncologists
Resources:
Slides
Webcast
LBA53 - Alliance A021602: Phase III, double-blinded study of cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET)
Presenter: Jennifer Chan
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast